Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 2166 participants.

Also called NCT04951856

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,166 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04951856
  • EudraCT 2021-000573-80
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04951856. Randomized; no masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2026-05-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
Acronym
AMUNDSEN
Condition
STEMI - ST Elevation Myocardial Infarction
Condition
NSTEMI - Non-ST Segment Elevation MI
Intervention (Drug)
Evolocumab 140 MG/ML
Intervention (Drug)
Standard of care (SOC)
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Action Research Group (class: other)
Collaborator
Amgen (class: industry)

Record details

Record id
cardio:ct-nct04951856
Content hash
b12c56098b8fc92ef269eb469bd42b17f69114733438e9e21e9ce28b07a0938f